Loading...
•
Sep 30, 2020
Iovance Q3 2020 Earnings Report
Reported third quarter 2020 financial results and provided a corporate update.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $58.6 million, or $0.40 per share, for the third quarter ended September 30, 2020. The company held $719.7 million in cash, cash equivalents, short-term investments and restricted cash at September 30, 2020.
BLA submission date for lifileucel moved to 2021 to reach agreement on required potency assays.
Registration-directed study initiated in non-small cell lung cancer.
Initial clinical data of TIL in combination with anti-PD-1 therapy in head and neck cancer to be presented.
Financial strength allows advancement of clinical programs and continuation of operating plans.
Forward Guidance
The company anticipates that the year-end balance of cash, cash equivalents, short-term investments and restricted cash may be over $630 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...